• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 3:42:04 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $BASI alert in real time by email
    SC 13G 1 bsi13g-021621.htm
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C.  20549
    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No.)*
    Bioanalytical Systems, Inc.
    (Name of Issuer)
    Common Shares, no par value
    (Title of Class of Securities)
    09058M103
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    IsZo Capital LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    760,015
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    760,015
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    760,015
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.8%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    PN



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    IsZo Capital GP LLC
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    760,015
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    760,015
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    760,015
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.8%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    OO



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    IsZo Capital Management LP
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    760,015
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    760,015
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    760,015
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.8%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    PN



    1.
    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
     
    Brian L. Sheehy
       
    2.
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
     
    (a)    [x]
     
    (b)    [ ]
       
    3.
    SEC USE ONLY
       
    4.
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
    United States
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
       
    5.
    SOLE VOTING POWER
       
     
    0
       
    6.
    SHARED VOTING POWER
       
     
    760,015
       
    7.
    SOLE DISPOSITIVE POWER
       
     
    0
       
    8.
    SHARED DISPOSITIVE POWER
       
     
    760,015
       
    9.
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     
    760,015
       
    10.
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
    EXCLUDES CERTAIN SHARES    [ ]
       
    11.
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     
    6.8%
       
    12.
    TYPE OF REPORTING PERSON
       
     
    IN, HC



    This Schedule 13G reflects the beneficial ownership of the Reporting Persons (as defined below) as of December 31, 2020.
    Item 1(a).
    Name of Issuer:
    Bioanalytical Systems, Inc. (“Issuer”)
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
    2701 Kent Avenue
    West Lafayette, Indiana 47906

    Item 2(a).
    Name of Persons Filing:
    The names of the persons filing this statement on Schedule 13G are (collectively, the “Reporting Persons”):
    -            IsZo Capital LP (the “Fund”).
    -            IsZo Capital GP LLC (“IsZo GP”).
    -            IsZo Capital Management LP (“ICM”).
    -            Brian L. Sheehy (“Mr. Sheehy”).
    IsZo GP is the general partner of the Fund.  ICM is the investment manager of the Fund.  Mr. Sheehy is the managing member of IsZo GP and the President of the general partner of ICM.  IsZo GP, ICM and Mr. Sheehy may each be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) held by the Fund.
    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
    Each of the Reporting Persons has a business address at 590 Madison Avenue, 21st Floor, New York, New York 10022.
    Item 2(c).
    Citizenship:
    Mr. Sheehy is a citizen of the United States.
    IsZo GP is a limited liability company formed under the laws of the State of Delaware.
    Each of the Fund and ICM is a limited partnership formed under the laws of the State of Delaware.
    Item 2(d).
    Title of Class of Securities:
    Common Shares, no par value (the “Common Stock”)
    Item 2(e).
    CUSIP Number:
    09058M103


    Item 3.
    If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Exchange Act.
           
     
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Exchange Act.
           
     
    (c)
    [ ]
    Insurance company defined in Section 3(a)(19) of the Exchange Act.
           
     
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act.
           
     
    (e)
    [ ]
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
     
    (f)
    [ ]
    Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
     
    (g)
    [ ]
    Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
     
    (h)
    [ ]
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
     
    (i)
    [ ]
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
     
    (j)
    [ ]
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    [ ]
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

    If this statement is filed pursuant to Rule 13d-1(c), check this box [  ]
    Item 4.
    Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a)
    Amount beneficially owned:
    As of the close of business on December 31, 2020, the Reporting Persons may be deemed to have beneficially owned 760,015 shares of Common Stock.

    (b)
    Percent of class:
    The aggregate percentage of Common Stock reported owned by each person named herein is based upon 11,131,256 shares outstanding, which is the total number of common shares outstanding on February 5, 2021 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on February 10, 2021. As of the close of business on December 31, 2020, the Reporting Persons may be deemed to have beneficially owned approximately 6.8% of Common Stock outstanding.

    (c)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote
    See Cover Pages Items 5-9.



    (ii)
    Shared power to vote or to direct the vote
    See Cover Pages Items 5-9.

    (iii)
    Sole power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.

    (iv)
    Shared power to dispose or to direct the disposition of
    See Cover Pages Items 5-9.
    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.
    See Exhibit B.
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
    Item 10.
    Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES
    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
    Dated:  February 16, 2021
     
    ISZO CAPITAL LP
     
    By IsZo Capital GP LLC, its General Partner
       
       
    By:
    /s/ Brian L. Sheehy 
         
    Brian L. Sheehy, Managing Member

     
    ISZO CAPITAL GP LLC
       
     
    By:
    /s/ Brian L. Sheehy 
       
    Brian L. Sheehy, Managing Member

     
    ISZO CAPITAL MANAGEMENT LP
     
    By: IsZo Management Corp., as General Partner
       
       
    By:
    /s/ Brian L. Sheehy 
         
    Brian L. Sheehy, Managing Member

     
    /s/ Brian L. Sheehy 
     
    Brian L. Sheehy





    EXHIBIT A
    JOINT FILING AGREEMENT
    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Bioanalytical Systems, Inc. dated February 16, 2021, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
    Dated:  February 16, 2021
     
    ISZO CAPITAL LP
     
    By IsZo Capital GP LLC, its General Partner
       
       
    By:
    /s/ Brian L. Sheehy 
         
    Brian L. Sheehy, Managing Member

     
    ISZO CAPITAL GP LLC
       
     
    By:
    /s/ Brian L. Sheehy 
       
    Brian L. Sheehy, Managing Member

     
    ISZO CAPITAL MANAGEMENT LP
     
    By: IsZo Management Corp., as General Partner
       
       
    By:
    /s/ Brian L. Sheehy 
         
    Brian L. Sheehy, Managing Member

     
    /s/ Brian L. Sheehy 
     
    Brian L. Sheehy



    EXHIBIT B
    IsZo Capital LP
    IsZo Capital GP LLC
    IsZo Capital Management LP
    Brian L. Sheehy
    Get the next $BASI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BASI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BASI
    SEC Filings

    View All

    SEC Form RW filed by Bioanalytical Systems, Inc.

    RW - Basis Global Technologies, Inc. (0001330016) (Filer)

    11/3/22 2:09:08 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed by Bioanalytical Systems, Inc.

    8-K - Inotiv, Inc. (0000720154) (Filer)

    3/19/21 4:30:11 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 8-K filed

    8-K - BIOANALYTICAL SYSTEMS INC (0000720154) (Filer)

    3/9/21 6:06:06 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Colliers Securities resumed coverage on Bioanalytical Systems with a new price target

    Colliers Securities resumed coverage of Bioanalytical Systems with a rating of Buy and set a new price target of $17.00

    3/9/21 4:15:07 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Beth Taylor bought $88,500 worth of Common Shares (5,000 units at $17.70), increasing direct ownership by 17% to 34,295 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    3/5/21 4:41:23 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4: Gregory John Beattie bought $31,843 worth of Common Shares (1,712 units at $18.60), increasing ownership by 7% to 25,000 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    3/1/21 4:14:24 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4: Gregory John Beattie bought $116,032 worth of Common Shares (8,288 units at $14.00), increasing ownership by 55% to 23,288 units

    4 - BIOANALYTICAL SYSTEMS INC (0000720154) (Issuer)

    2/25/21 4:03:55 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc.

    WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company’s corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. The name change was approved by the Company’s shareholders on March 18, 2021, at the Company’s annual meeting of shareholders and became effective as of the filing of articles of amendment to the Company’s Second Amended and Restated Articles of Incorporation, as amended, that same day. Effective Monday, March 22, 2021, The Company’s common shares will trade under the ti

    3/19/21 4:05:00 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology

    WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company’s service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacology. Safety pharmacology evaluations are critical for assessing the impact of drug candidates. By summer 2021, Inotiv expects to offer integrated safety pharmacology packages that include core battery tests for cardiovascular, respiratory, and ce

    3/17/21 8:33:00 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bioanalytical Systems, Inc., doing business as Inotiv, Invests in Additional Vivarium Capacity at Facility in West Lafayette, IN

    WEST LAFAYETTE, Ind., March 09, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services continues to invest in expanding services and adding capacity to meet client needs and growth expectations. In line with these goals, the Company has been expanding and further developing its West Lafayette vivarium. Last month, the additional West Lafayette capacity was successfully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council. The Company believes this is an important step fo

    3/9/21 8:33:00 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed

    SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/16/21 3:42:04 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed

    SC 13G - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/10/21 9:57:05 AM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BIOANALYTICAL SYSTEMS INC (0000720154) (Subject)

    2/3/21 1:35:55 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $BASI
    Leadership Updates

    Live Leadership Updates

    View All

    Bioanalytical Systems, Inc., doing business as Inotiv, Appoints Greg Beattie as Chief Operating Officer

    WEST LAFAYETTE, Ind., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced the appointment of Greg Beattie as Chief Operating Officer of the Company, effective February 15, 2021. Mr. Beattie brings more than 30 years of contract research experience to the Company, including more than two decades in operational leadership roles at Charles River Laboratories, where he drove growth and profitability across multiple business units. During his career at Charles River Laboratories, Mr. Beattie held Corporate Vice

    2/11/21 4:05:00 PM ET
    $BASI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care